PROSTATE CANCER Time for active surveillance of intermediate-risk disease?

被引：7
|
作者：
Ahmed, Hashim U. [1 ]
机构：
[1] UCL, Div Surg & Intervent Sci, London WC1E 6AU, England
来源：
NATURE REVIEWS UROLOGY | 2013年 / 10卷 / 01期
基金：
英国医学研究理事会;
关键词：
MANAGEMENT;
D O I：
10.1038/nrurol.2012.213
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
Active surveillance has become increasingly popular as a management option for localized prostate cancer. Although widely viewed as a means to enable men with low-risk prostate cancer to avoid or defer the effects of whole-gland radical therapy, two new studies demonstrate that it might be a safe approach in intermediate-risk disease. Ahmed, H. U. Nat. Rev. Urol. 10, 6-8 (2013); published online 13 November 2012; doi:10.1038/nrurol.2012.213
引用
收藏
页码：6 / 8
页数：4
相关论文
共 50 条
  • [41] Adverse Disease Features in Gleason Score 3+4 "Favorable Intermediate-Risk'' Prostate Cancer: Implications for Active Surveillance
    Morlacco, Alessandro
    Cheville, John C.
    Rangel, Laureano J.
    Gearman, Derek J.
    Karnes, R. Jeffrey
    [J]. EUROPEAN UROLOGY, 2017, 72 (03) : 442 - 447
  • [42] Insignificant disease among men with intermediate-risk prostate cancer
    Hong, Sung Kyu
    Vertosick, Emily
    Sjoberg, Daniel D.
    Scardino, Peter T.
    Eastham, James A.
    [J]. WORLD JOURNAL OF UROLOGY, 2014, 32 (06) : 1417 - 1421
  • [43] Insignificant disease among men with intermediate-risk prostate cancer
    Sung Kyu Hong
    Emily Vertosick
    Daniel D. Sjoberg
    Peter T. Scardino
    James A. Eastham
    [J]. World Journal of Urology, 2014, 32 : 1417 - 1421
  • [44] Role of active surveillance and focal therapy in low- and intermediate-risk prostate cancers
    van der Poel, Henk
    Klotz, Laurence
    Andriole, Gerald
    Azzouzi, Abdel-Rahmene
    Bjartell, Anders
    Cussenot, Olivier
    Hamdy, Freddy
    Graefen, Markus
    Palma, Paolo
    Rodriguez Rivera, Arturo
    Stief, Christian G.
    [J]. WORLD JOURNAL OF UROLOGY, 2015, 33 (07) : 907 - 916
  • [45] Role of active surveillance and focal therapy in low- and intermediate-risk prostate cancers
    Henk van der Poel
    Laurence Klotz
    Gerald Andriole
    Abdel-Rahmène Azzouzi
    Anders Bjartell
    Olivier Cussenot
    Freddy Hamdy
    Markus Graefen
    Paolo Palma
    Arturo Rodriguez Rivera
    Christian G. Stief
    [J]. World Journal of Urology, 2015, 33 : 907 - 916
  • [46] Active surveillance in males with low- to intermediate-risk localized prostate cancer: A modern prospective cohort study
    Rakauskas, Arnas
    Tawadros, Thomas
    Lucca, Ilaria
    Herrera, Fernanda
    Bourhis, Jean
    Burruni, Rodolfo
    Gomes, Maria Natal
    Codeluppi, Caroline
    Jolliet, Laura
    La Rosa, Stefano
    Meuwly, Jean Yves
    Jichlinski, Patrice
    Berthold, Dominik
    Valerio, Massimo
    [J]. INVESTIGATIVE AND CLINICAL UROLOGY, 2021, 62 (04) : 416 - 422
  • [47] Recommendations of Active Surveillance for Intermediate-risk Prostate Cancer: Results from a National Survey of Radiation Oncologists and Urologists
    Kim, Simon P.
    Shah, Nilay D.
    Meropol, Neal J.
    Tilburt, Jon C.
    Nguyen, Paul L.
    Yu, James B.
    Abouassaly, Robert
    Kim, Albert
    Gross, Cary P.
    [J]. EUROPEAN UROLOGY ONCOLOGY, 2019, 2 (02): : 189 - 195
  • [48] Influence of Active Surveillance on Gleason Score Upgrade and Prognosis in Low- and Favorable Intermediate-Risk Prostate Cancer
    Hu, Xuanhan
    Miao, Jia
    Huang, Jiaqing
    Qian, Lin
    Zhang, Dahong
    Wei, Haibin
    [J]. CURRENT ONCOLOGY, 2022, 29 (10) : 7964 - 7978
  • [49] Active surveillance-much safety, little recruitment Is it possible to extend the indication for "intermediate-risk" prostate cancer?
    Weissbach, Lothar
    Boedefeld, Edith A.
    Herden, Jan
    [J]. UROLOGE, 2021, 60 (10): : 1304 - 1312
  • [50] Active surveillance selection and 3-year durability in intermediate-risk prostate cancer following genomic testing
    Lenz, Lauren
    Clegg, Wyatt
    Iliev, Diana
    Kasten, Chelsea R.
    Korman, Howard
    Morgan, Todd M.
    Hafron, Jason
    DeHaan, Alexander
    Olsson, Carl
    Tutrone Jr, Ronald F.
    Richardson, Timothy
    Cline, Kevin
    Yonover, Paul M.
    Jasper, Jeff
    Cohen, Todd
    Finch, Robert
    Slavin Jr, Thomas P.
    Gutin, Alexander
    [J]. PROSTATE CANCER AND PROSTATIC DISEASES, 2024,
12345